Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines

  • Toshio Sasajima
  • Tadashi Miyagawa
  • Takamitsu Oku
  • Juri G. Gelovani
  • Ronald Finn
  • Ronald BlasbergEmail author
Original Article


Amino acid imaging is increasingly being used for assessment of brain tumor malignancy, extent of disease, and prognosis. This study explores the relationship between proliferative activity, amino acid transport, and glucose metabolism in three glioma cell lines (U87, Hs683, C6) at different phases of growth in culture. Growth phase was characterized by direct cell counting, proliferation index determined by flow cytometry, and [3H]thymidine (TdR) accumulation, and was compared with the uptake of two non-metabolized amino acids ([14C]aminocyclopentane carboxylic acid (ACPC) and [14C]aminoisobutyric acid (AIB)), and [18F]fluorodeoxyglucose (FDG). Highly significant relationships between cell number (density), proliferation index, and TdR accumulation rate were observed in all cell lines (r>0.99). Influx (K1) of both ACPC and AIB was directly related to cell density, and inversely related to the proliferation index and TdR accumulation in all cell lines. The volume of distribution (V d ) for ACPC and AIB was lowest during rapid growth and highest during the near-plateau growth phase in all cell lines. FDG accumulation in Hs683 and C6 cells was unaffected by proliferation rate, growth phase, and cell density, whereas FDG accumulation was correlated with TdR accumulation, growth phase, and cell density in U87 cells. This study demonstrates that proliferation rate and glucose metabolism are not necessarily co-related in all glioma cell lines. The values of K1 and V d for ACPC and AIB under different growth conditions suggest that these tumor cell lines can up-regulate amino acid transporters in their cell membranes when their growth conditions become adverse and less than optimal.


Tumor proliferation Non-metabolized amino acid transport 18F-fluorodeoxyglucose Gliomas 



The authors wish to thank Zakia M. Coriaty for her excellent technical assistance. This work was supported by NIH Grants R01 CA60706, P50 CA86438, and R24 CA83084 and DOE grant 86-ER60407.


  1. 1.
    Bergström M, Lundqvist H, Ericson K, Lilja A, Johnström P, Långström B, von Holst H, Eriksson L, Blomqvist G. Comparison of the accumulation kinetics ofl-(methyl-11C)-methionine and d-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 1987; 28:225–229.PubMedGoogle Scholar
  2. 2.
    Lilja A, Lundqvist H, Olsson Y, Spännare B, Gullberg P, Långström B. Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions. Acta Radiol 1989; 30:121–128.PubMedGoogle Scholar
  3. 3.
    Roelcke U, Radü E, Ametamey S, Pellikka R, Steinbrich W, Leenders KL. Association of82Rubidium and 11C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol 1996; 27:163–171.PubMedGoogle Scholar
  4. 4.
    Wienhard K, Herholz K, Coenen HH, Rudolf J, Kling P, Stöcklin G, Heiss WD. Increased amino acid transport into brain tumors measured by PET ofl-(2-18F)fluorotyrosine. J Nucl Med 1991; 32:1338–1346.PubMedGoogle Scholar
  5. 5.
    Miura S, Murakami M, Kanno I, Iida H, Uemura K. Phenylalanine transport in the living human brain by a dynamic PET ofl-[2-18F]-fluorophenylalanine [in Japanese]. Nippon Rinsho 1992; 50:1457–1460.PubMedGoogle Scholar
  6. 6.
    Ito H, Hatazawa J, Murakami M, Miura S, Iida H, Bloomfield PM, Kanno I, Fukuda H, Uemura K. Aging effect on neutral amino acid transport at the blood-brain barrier measured withl-[2-18F]-fluorophenylalanine and PET. J Nucl Med 1995; 35:1232–1237.Google Scholar
  7. 7.
    Ogawa T, Miura S, Murakami M, Iida H, Hatazawa J, Inugami A, Kanno I, Yasui N, Sasajima T, Uemura K. Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine-18 fluorophenylalanine. Eur J Nucl Med 1996; 23:889–895.PubMedGoogle Scholar
  8. 8.
    Christensen HN. Role of animo acid transport and countertransport in nutrition and metabolism. Phys Rev 1990; 70:43–77.Google Scholar
  9. 9.
    Miyagawa T, Oku T, Uehara H, Desai R, Beattie B, Tjuvajev J, Blasberg R. “Facilitated” amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998; 18:500–509.CrossRefPubMedGoogle Scholar
  10. 10.
    Miyagawa T, Oku T, Sasajima T, Dasai R, Beattie B, Finn R, Tjuvajev JG, Blasberg R. Assessment of treatment response by autoradiography with14C-aminocyclopentane carboxylic acid, 67Ga-DTPA, and 18F-FDG in a herpes simplex virus thymidine kinase/ganciclovir brain tumor model. J Nucl Med 2003; 44:1845–1854.PubMedGoogle Scholar
  11. 11.
    Langen KJ, Ziemons K, Kiwit JCW, Herzog H, Kuwert T, Bock WJ, Stöcklin G, Feinendegen LE, Müller-Gärtner HW. 3-[123I] iodo-α-methyltyrosine and [methyl-11C]-l-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med 1997; 38:517–522.PubMedGoogle Scholar
  12. 12.
    Samnick S, Bader JB, Hellwig D, Moringlane JR, Alexander C, Romeike BFM, Feiden W, Kirsch CM. Clinical value of iodine-123-alpha-methyl-l-tyrosine single-photon emission tomography in the differential diagnosis of recurrent brain tumor in patients pretreated for glioma at follow-up. J Clin Oncol 2002; 20:396–404.CrossRefPubMedGoogle Scholar
  13. 13.
    Derlon JM, Bourdet C, Bustany P, Chatel M, Theron J, Darcel F, Syrota A. [11C] l-methionine uptake in gliomas. Neurosurgery 1989; 25:720–728.PubMedGoogle Scholar
  14. 14.
    Kameyama M, Shirane R, Itoh J, Sato K, Katakura R, Yoshimoto T, Hatazawa J, Itoh M, Ido T.. The accumulation of11C-methionine in cerebral glioma patients studied with PET. Acta Neurochir (Wien) 1990; 104:8–12.Google Scholar
  15. 15.
    De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 2001; 95:746–750.PubMedGoogle Scholar
  16. 16.
    Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, Shimosegawa E, Ito H, Hatazawa J, Okudera T, Uemura K, Yasui N, Mineura K. Cerebral glioma: evaluation with methionine PET. Radiology 1993; 186:45–53.PubMedGoogle Scholar
  17. 17.
    Mineura K, Kowada M, Shishido F. Brain tumor imaging with synthesized18F-fluorophenylalanine and positron emission tomography. Surg Neurol 1989; 31:468–469.PubMedGoogle Scholar
  18. 18.
    Hatazawa J, Itoh H, Shimosegawa E, Kanno I, Murakami M, Miura S, Iida H, Okudera T, Inugami A, Ogawa T, Fujita H, Satoh Y, Nagata K, Hirata Y, Uemura K. Accumulation ofl-[2-(F-18)]fluorophenylalanine in peri-infarct area in a patient with acute cerebral infarction. Ann Nucl Med 1994; 8:213–217.PubMedGoogle Scholar
  19. 19.
    Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Uemura K. Indications for differential diagnosis of nontumor central nervous system diseases from tumors. A positron emission tomography study. J Neuroimag 1997; 7:8–15.Google Scholar
  20. 20.
    Warburg O. On the origin of cancer cells. Science 1956; 123:309–314.PubMedGoogle Scholar
  21. 21.
    Mineura K, Sasajima T, Kowada M, Ogawa T, Hatazawa J, Shishido F, Uemura K. Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 1994; 73:2386–2394.PubMedGoogle Scholar
  22. 22.
    Di Chiro G, Brooks RA, Patronas NJ, Bairamian D, Kornblith PL, Smith BH, Mansi L, Barker J. Issues in the in vivo measurement of glucose metabolism of human central nervous system tumor. Ann Neurol 1984; 15(Suppl):S138–S146.Google Scholar
  23. 23.
    Herholz K, Pietrzyk U, Voges J, Schröder R, Halber M, Treuer H, Sturm V, Heiss WD. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 1993; 79:853–858.PubMedGoogle Scholar
  24. 24.
    Altman SA, Randers L, Rao G. Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. Biotechnol Prog 1993; 9:671–674.PubMedGoogle Scholar
  25. 25.
    Winsor CP. The Gompertz curve as a growth curve. Proc Natl Acad Sci U S A 1932; 18:1–8.Google Scholar
  26. 26.
    Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F] fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235–238.PubMedGoogle Scholar
  27. 27.
    Merkel DE, McGuire WL. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors. Cancer 1990; 65:1194–1205.PubMedGoogle Scholar
  28. 28.
    Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34:414–419.PubMedGoogle Scholar
  29. 29.
    Guidotti GG, Borghetti AF, Gazzola GC. The regulation of amino acid transport in animal cells. Biochim Biophys Acta 1978; 515:329–366.Google Scholar
  30. 30.
    Shotwell MA, Kilberg MS, Oxender DL. The regulation of neutral amino acid transport in mammalian cells. Biochim Biophys Acta 1983; 737:267–284.PubMedGoogle Scholar
  31. 31.
    Wang H, Huang W, Sugawara M, Devoe LD, Leibach FH, Prasad PD, Ganapathy V. Cloning and functional expression of ATA1, a subtype of amino acid transporter A, from human placenta. Biochem Biophys Res Commun 2000; 273:1175–1179.CrossRefPubMedGoogle Scholar
  32. 32.
    Sugawara M, Nakanishi T, Fei YJ, Martindale RG, Ganapathy ME, Leibach FH, Ganapathy V. Structure and function of ATA3, a new subtype of amino acid transport system A, primarily expressed in the liver and skeletal muscle. Biochim Biophys Acta 2000; 1509:7–13.PubMedGoogle Scholar
  33. 33.
    Hatanaka T, Huang W, Martindale RG, Ganapathy V. Differential influence of cAMP on the expression of the three subtypes (ATA1, ATA2, and ATA3) of the amino acid transport system A. FEBS Lett 2001; 505:317–320.CrossRefPubMedGoogle Scholar
  34. 34.
    Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998; 273:23629–23632.PubMedGoogle Scholar
  35. 35.
    Pineda M, Fernández E, Torrents D, Estévez R, López C, Camps M, Lloberas J, Zorzano A, Palacín M. Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids. J Biol Chem 1999; 274:19738–19744.PubMedGoogle Scholar
  36. 36.
    Segawa H, FukasawaY, Miyamoto K, Takeda E, Endou H, Kanai Y. Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem 1999; 274:19745–19751.PubMedGoogle Scholar
  37. 37.
    Campbell WA, Sah DE, Medina MM, Albina JE, Coleman WB, Thompson NL. TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells. Loss of response in tumor cells. J Biol Chem 2000; 275:5347–5354.PubMedGoogle Scholar
  38. 38.
    Langen KJ, Mühlensiepen H, Holschbach M, Hautzel H, Jansen P, Coenen HH. Transport mechanisms of 3-[123I]iodo-α-methyl-l-tyrosine in a human glioma cell line: comparison with [3H]methyl]-l-methionine. J Nucl Med 2000; 41:1250–1255.PubMedGoogle Scholar
  39. 39.
    Langen KJ, Bonnie R, Mühlensiepen H, Jansen P, Bröer S, Holschbach M, Coenen HH. 3-[123I]iodo-α-methyl-l-tyrosine transport and 4F2 antigen expression in human glioma cells. Nucl Med Biol 2001; 28:5–11.CrossRefPubMedGoogle Scholar
  40. 40.
    Minn H, Clavo AC, Grénman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose andl-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 1995; 36:252–258.PubMedGoogle Scholar
  41. 41.
    Haberkorn U, Ziegler SI, Oberdorfer F, Trojan H, Haag D, Peschke P, Berger MR, Altmann A, van Kaick G. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994; 21:827–834.PubMedGoogle Scholar
  42. 42.
    Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996; 37:1042–1047.PubMedGoogle Scholar
  43. 43.
    Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, Honda T, Inokuma T, Katsushima S, Ohshio G, Imamura M, Konishi J. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39:1727–1735.PubMedGoogle Scholar
  44. 44.
    Waki A, Kato H, Yano R, Sadato N, Yokoyama A, Ishii Y, Yonekura Y, Fujibayashi Y. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol 1998; 25:593–597.PubMedGoogle Scholar
  45. 45.
    Marom EM, Aloia TA, Moore MB, Hara M, Herndon JE 2nd, Harpole DH Jr, Goodman PC, Patz EF Jr. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 2001; 33:99–107.PubMedGoogle Scholar
  46. 46.
    Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, Yasuda S. Significance of18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002; 9:15–18.CrossRefPubMedGoogle Scholar
  47. 47.
    Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol Imaging 2004; 31:5–12.CrossRefPubMedGoogle Scholar
  48. 48.
    Nelson CA, Wang JQ, Leav I, Crane PD. The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 1996; 23:533Tian M, Zhang H, Nakasone Y, Mogi K, Endo K541.Google Scholar
  49. 49.
    Aloj L, Caracó C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-d-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999; 59:4709–4714.PubMedGoogle Scholar
  50. 50.
    Bos R, van Der Hoeven JJM, van Der Wall E, van Der Groep P, van Diest PJ, Comans EFI, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CFM. Biologic correlates of18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002; 20:379–387.PubMedGoogle Scholar
  51. 51.
    Higashi T, Saga T, Nakamoto Y, Ishimori T, Mamede MH, Wada M, Doi R, Hosotani R, Imamura M, Konishi J. Relationship between retention index in dual-phase18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002; 43:173–180.PubMedGoogle Scholar
  52. 52.
    Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL. Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 2002; 29:443–453.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Toshio Sasajima
    • 1
    • 3
  • Tadashi Miyagawa
    • 1
    • 4
  • Takamitsu Oku
    • 1
    • 5
  • Juri G. Gelovani
    • 1
    • 2
    • 6
  • Ronald Finn
    • 2
  • Ronald Blasberg
    • 1
    • 2
    Email author
  1. 1.Department of Neurology, C799Memorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of RadiologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Neurosurgical ServiceAkita University HospitalAkitaJapan
  4. 4.Department of NeurosurgeryChiba University School of MedicineChuo-ku, ChibaJapan
  5. 5.Department of NeurosurgeryMiyazaki Medical CollegeMiyazakiJapan
  6. 6.Department of Experimental Diagnostic ImagingThe University of Texas, MD Anderson Cancer CenterHoustonUSA

Personalised recommendations